CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Welichem Biotech Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Welichem Biotech Inc.
316-4475 Wayburne Dr
Phone: (604) 432-1703p:604 432-1703 Burnaby, BC  V5G 3L1  Canada Ticker: WBI WBI
Business Summary
Welichem Biotech Inc. is a Canada-based drug discovery and early stage drug development company focusing on novel therapeutics for unmet medical needs including autoimmune and inflammatory diseases and cancers. The Company’s drug candidate, WBI-1001, was developed by the Company as a topical treatment for inflammatory skin diseases such as psoriasis and atopic dermatitis. It entered into an Asset Purchase Agreement with Stiefel, a Glaxo Group Limited company, for all the rights to the WBI-1001 technology. The Company’s other unique drug candidate, WBI-2100 and its analogous, which is in the pre-clinical stage of development, has unique dual activities of anti-cancer activity together with neutrophil boosting activity. Both WBI-1001 and WBI-2100 series compounds are derived from the metabolites of bacterial symbionts of soil living nematodes.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
2/28/20145/31/2013Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer LirenTang 11/10/2009 11/10/2009
Chief Financial Officer, Secretary Harvey S.Quan 1/14/2011 12/17/2010
Vice President - Research & Development MLyle 11/10/2009 11/10/2009
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 59,462,658 (As of 3/13/2014)
Stock Exchange: CVE
Fax Number: (604) 432-1703


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023